What one share of Moonlake Immunotherapeutics holds
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Moonlake Immunotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.82 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.26 |
| Cash and investments | $5.62 |
| Debt | $1.17 |
| Book value | $5.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.31 | — | — | — | −$0.98 |
| 2022 | — | −$1.70 | $0.00 | −$1.90 | — | $1.67 |
| 2023 | — | −$0.73 | $0.01 | −$0.88 | — | $10.09 |
| 2024 | — | −$1.89 | $0.01 | −$1.86 | — | $7.11 |
| 2025 | — | −$3.53 | $0.00 | −$3.04 | — | $4.72 |
Common questions about Moonlake Immunotherapeutics
How much does one share of Moonlake Immunotherapeutics earn?
Over the last 12 months, Moonlake Immunotherapeutics lost $3.82 for each share.
Does Moonlake Immunotherapeutics pay a dividend?
Moonlake Immunotherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Moonlake Immunotherapeutics’s book value per share?
Moonlake Immunotherapeutics’s book value is $5.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Moonlake Immunotherapeutics have?
Each share of Moonlake Immunotherapeutics has $5.62 of cash and investments and $1.17 of debt, as of June 30, 2026.
What is Moonlake Immunotherapeutics’s free cash flow per share?
−$3.26 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Moonlake Immunotherapeutics bought back shares?
Moonlake Immunotherapeutics’s share count rose about 340% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.